This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Ligand (LGND) Beats on Q1 Earnings & Sales, Raises View
by Zacks Equity Research
Ligand (LGND) reports higher-than-expected first-quarter 2020 earnings and revenues.
Ultragenyx (RARE) Q1 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected first-quarter 2020 loss.
Mallinckrodt (MNK) Q1 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Mallinckrodt (MNK) declines on sales miss in the first quarter and a challenging outlook for the remainder of the year despite reporting an earnings beat.
Alexion (ALXN) Beats on Q1 Earnings & Sales, Lowers Guidance
by Zacks Equity Research
Alexion (ALXN) beats on earnings and sales in the first quarter of 2020 but lowers view due to the ongoing pandemic.
Simple Secrets Anyone Can Use to Reach Early Retirement - May 05, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Remdesivir Gets Emergency Approval: What's In Store for Gilead?
by Zacks Equity Research
In a short span of time, Gilead's Remdesivir has been successful in treating some coronavirus patients. But will this give a boost to the pharmaceutical giant?
Amgen (AMGN) Q1 Earnings Top, to Study Otezla for Coronavirus
by Zacks Equity Research
Amgen (AMGN) beats estimates for both earnings and sales. It maintains its previously-issued financial guidance for 2020.
Gilead (GILD) Q1 Earnings Top, Coronavirus Candidate in Focus
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the first quarter but the uncertain outlook for the year dampens investors' hopes.
The Zacks Analyst Blog Highlights: Amazon, Apple, Gilead Sciences, Amgen and Visa
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Apple, Gilead Sciences, Amgen and Visa
Amazon Misses on Earnings, Apple Beats but Trades Lower
by Mark Vickery
Amazon came in well below earnings estimates, Apple beats on both top & bottom, plus results from Gilead, Amgen and Visa.
Amgen (AMGN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 12.70% and 2.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
The Extreme Risks of Trading Your Own Retirement Assets - April 30, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat
by Ritujay Ghosh
A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.
Is a Beat in Store for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More
by Zacks Equity Research
Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Amgen's (AMGN) performance when it reports first-quarter results.
Pfizer (PFE) Q1 Earnings Top, Biopharma Gains From Coronavirus
by Zacks Equity Research
Pfizer (PFE) beats estimates for earnings. While the coronavirus pandemic hurts sales of some Pfizer medicines, it benefited sales of others, resulting in a net positive benefit on total sales.
Want To Retire Early? Learn the Intelligent Investing Secret - April 27, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Focus on Coronavirus Treatments to Boost Biotech Stocks
by Zacks Equity Research
With the coronavirus pandemic raging on, biotech companies are in focus as they are racing against time to evaluate every possible therapy to combat the spread.
Will Pfizer's (PFE) BioPharma Unit Q1 Earnings Increase?
by Zacks Equity Research
In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the first quarter, while in non-oncology, Xeljanz and Eliquis alliance revenues are likely to have supported the top line.
Amgen (AMGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lilly (LLY) Q1 Earnings Beat, Coronavirus May Mar Profits
by Zacks Equity Research
Eli Lilly (LLY) beat estimates for both earnings and sales in the first quarter of 2020. However, the company warns that coronavirus-related uncertainty may hurt financial results in 2020 and beyond.
Healthcare ETFs Looks Strong Ahead of Q1 Earnings
by Sweta Killa
The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.
Roche (RHHBY) Q1 Sales Grow on Solid Performance of New Drugs
by Zacks Equity Research
Solid sales of Roche's (RHHBY) new drugs in the first quarter more than offset the competition from biosimilars.
Biotech ETFs Gaining on Progress in Coronavirus Treatment
by Sweta Jaiswal, FRM
The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.